How Does Vivitrol Work?

People who used Vivitrol with rehabilitation and continuing therapy were 17 times less likely to relapse compared to those who did not use it. How Vivitrol works reveals why this medication has become a strong partner in addiction treatment. Vivitrol is the injectable brand name for naltrexone, a non-addictive medication that blocks opioid receptors in your brain. This blocking mechanism prevents the euphoric and rewarding sensations associated with opioids and alcohol and makes it easier for you to maintain sobriety.

Vivitrol uses extend to both alcohol and opioid dependence treatment. What does Vivitrol do? It binds to the same brain receptors that substances stimulate and neutralizes their pleasurable effects. In this piece, we explore the science behind Vivitrol’s mechanism and its FDA-approved applications. We also cover treatment considerations and why combining it with counseling produces optimal recovery outcomes.

What Is Vivitrol and What Does Vivitrol Do

Vivitrol as Injectable Naltrexone

Vivitrol represents a long-acting injectable formulation of naltrexone, an opioid antagonist medication used to treat substance use disorders. Oral naltrexone tablets require daily administration, but Vivitrol delivers the active ingredient through intramuscular injection. The medication is non-narcotic and not habit-forming. Vivitrol does not function as aversive therapy, meaning it won’t cause unpleasant reactions if you consume alcohol or opioids. This distinguishes it from medications like disulfiram that induce sickness upon substance use.

You must be opioid-free before receiving your first Vivitrol injection. The medication works differently than oral naltrexone in your body. Injectable naltrexone bypasses first-pass metabolism in the liver and results in a total monthly dose of 380 mg compared to 1,500 mg required for oral naltrexone over the same period. This reduced exposure means your liver receives much less peak concentration of the drug.

Monthly Extended-Release Formulation

Vivitrol has 380 mg of naltrexone in a microsphere formulation delivered as a single-dose injection. A healthcare provider administers the medication as a deep intramuscular gluteal injection every 4 weeks and alternates buttocks for subsequent injections. You cannot self-administer Vivitrol. Only trained healthcare professionals can prepare and deliver the injection.

The microsphere technology allows naltrexone to release slowly over 28 days. Plasma concentrations peak around 2 hours after injection, followed by a second peak 2 to 3 days later. Concentrations gradually decline beginning around day 7 while maintaining therapeutic blood levels throughout the four-week period. This steady release avoids the daily peaks and troughs associated with oral naltrexone.

FDA-Approved Vivitrol Uses for Addiction Treatment

The FDA first approved Vivitrol for treating alcohol dependence in 2006. You must be able to abstain from alcohol in an outpatient setting before starting treatment, and you should not be drinking at the time of your first dose. The FDA approved Vivitrol in 2010 for preventing relapse to opioid dependence following detoxification.

Vivitrol must be part of a management program that has psychosocial support. The medication alone does not constitute complete treatment. Combining Vivitrol with counseling and behavioral therapies forms medication-assisted treatment, which works better than medication or therapy alone.

The Science Behind How Vivitrol Works

Opioid Receptor Antagonist Mechanism

Naltrexone functions as a competitive antagonist at opioid receptors in your central and peripheral nervous systems. The medication demonstrates highest affinity for the mu-opioid receptor, with weaker antagonism at kappa and delta-opioid receptors. Naltrexone binds to these receptors without triggering intracellular signaling rather than activating them. This competitive binding prevents opioid agonists from attaching to the same receptors and blocks their pharmacological effects.

Blocking Euphoria and Rewarding Effects

Vivitrol blocks euphoric and sedative effects of opioids such as heroin, morphine, and codeine by occupying receptor sites. Alcohol stimulates endogenous opioid release (endorphins, enkephalins, dynorphins) that bind to opiate receptors and create pleasurable sensations when you drink it. Naltrexone blocks these endogenous opioids from activating mu-opioid receptors. The alcohol enters your system, but the endorphin-driven reward signal becomes substantially dampened. A single 50 mg dose achieves about 90 to 95% brain mu-opioid receptor occupancy.

Duration of Action in the Body

Naltrexone plasma concentration peaks about 2 hours post-injection after intramuscular injection and is followed by a second peak around 2 to 3 days later. Concentrations begin declining around day 14. Measurable drug levels persist for more than 1 month. Steady state occurs at the end of the dosing interval following your first injection. Minimal accumulation occurs (less than 15%) upon repeat administration.

Differences from Oral Naltrexone

Injectable Vivitrol bypasses first-pass hepatic metabolism and produces much less of the primary metabolite 6β-naltrexol compared to oral naltrexone. Total naltrexone exposure reaches 3 to 4-fold higher levels following a single 380 mg Vivitrol dose versus 28 days of daily oral naltrexone at 50 mg. This reduced first-pass metabolism means your liver receives lower peak drug concentrations with injectable formulation.

How Vivitrol Treats Alcohol and Opioid Dependence

Vivitrol for Alcohol Use Disorder

Vivitrol treats alcohol dependence by blocking the endorphins your brain releases at the time you consume alcohol. This neutralizes the pleasurable sensations that reinforce drinking behavior. Clinical trials demonstrate that patients receiving Vivitrol with counseling experienced 25% fewer heavy drinking days per month compared to those receiving placebo with counseling. Heavy drinking was defined as five or more standard drinks daily for men and four or more for women.

The medication proves especially effective when you abstain from alcohol for at least seven consecutive days before your first injection. A subset analysis of patients who managed to keep four days of abstinence prior to treatment showed those receiving Vivitrol with psychosocial support had a median of 0.2 heavy drinking days per month versus 2.9 days for the placebo group. Vivitrol also helps normalize brain chemistry over time and reduces the heightened response to drinking rewards.

Vivitrol for Opioid Addiction Recovery

Vivitrol prevents relapse following complete detoxification for opioid dependence. Patients using Vivitrol combined with counseling achieved 90% opioid-free weeks compared to 35% for those receiving placebo. Those who incorporated Vivitrol into rehabilitation and continuing therapy were 17 times less likely to relapse. Research confirms that injectable naltrexone produces extinction of drug-seeking behavior after opioid use episodes.

Why Complete Detox Is Required First

You must be opioid-free for a minimum of 7 to 10 days before starting Vivitrol treatment. This requirement prevents precipitated withdrawal, which can be severe enough to require hospitalization. Your healthcare provider may employ a naloxone challenge test if there is risk of triggering withdrawal reactions. If you start Vivitrol while physically dependent on opioids, you will experience sudden and dangerous withdrawal symptoms.

Vivitrol Side Effects and Treatment Considerations

Common Side Effects and Injection Site Reactions

Most patients experience headache, sleep disturbance, anxiety, dizziness, nausea, diarrhea, or rash. Injection site reactions occur frequently. Tenderness appears in 45% of patients and induration in 35%. Muscle cramps, decreased appetite, and cold symptoms also appear commonly. Injection site reactions are mild typically, but they can become severe. One patient developed enlarging induration after 4 weeks and needed surgical excision of necrotic tissue. Call your healthcare provider immediately if you notice intense pain, hardness, large swelling, lumps, blisters, open wounds, or dark scabs at injection sites.

Serious Risks: Liver Toxicity and Pneumonia

Concerns about hepatotoxicity led to an FDA black-box warning. The FDA removed it in 2013 due to lack of evidence. Serum enzyme elevations occur in about 1% of patients but remain mild and self-limiting. Eosinophilic pneumonia, though rare, represents a serious allergic reaction that requires hospitalization. Symptoms include progressive shortness of breath and low oxygen levels. Depression and suicidal thoughts constitute another most important risk that requires family monitoring.

Who Should Not Take Vivitrol

You cannot receive Vivitrol if currently using opioids, experiencing acute opioid withdrawal, or testing positive for opioids. You must remain opioid-free for 7 to 10 days minimum before starting treatment. Additional contraindications include hypersensitivity to naltrexone, liver problems, kidney issues, hemophilia, or bleeding disorders.

Importance of Combining Vivitrol with Counseling

Vivitrol must be part of detailed management that includes psychosocial support. The medication alone does not constitute complete treatment. Counseling addresses triggers and builds coping skills while developing relapse prevention strategies.

Conclusion

Vivitrol offers a scientifically proven approach to addiction recovery. The medication blocks opioid receptors in your brain and prevents the euphoric sensations that reinforce substance use. Its monthly injection format eliminates daily dosing concerns and maintains consistent therapeutic levels. You must combine Vivitrol with counseling and behavioral therapy to address everything psychological in addiction. This integrated approach improves your chances of maintaining long-term sobriety and rebuilding your life by a lot.